REGENSBURG, GERMANY--(Marketwire - November 10, 2010) -
Geneart AG /
GENEART AG: Preliminary Group Results (IFRS) for QIII/2010
Processed and transmitted by Thomson Reuters.
The issuer is solely responsible for the content of this announcement.
* Continued stable development during the third quarter 2010
* Slightly positive operating results after nine months
* Validation of the annual prognosis 2010
GENEART AG increased its net Group sales by
13.1% during the first nine months of 2010 and thus continued its
development of the previous quarters. Nine-month net sales increased
12.4M to EUR 14.0M. The third quarter 2010 ended with net sales of EUR
This is an increase of 16.2% over the previous year's reference period,
4.3M were generated.
Operating performance remained largely unaffected by Applied
Deutschland GmbH's takeover. Applied Biosystems Deutschland GmbH is an
subsidiary of Life Technologies Corporation.
GENEART showed positive results after nine months. The preliminary
result (EBIT in accordance with IFRS) totalled EUR 227 thousand compared
51 thousand in the prior year. The development of earnings
expected. GENEART generated an EBIT of EUR 135 thousand (prior year:
thousand) at Group level during the third quarter 2010.
The IFRS results of the first six months were affected by a
extraordinary item of EUR 408 thousand relating to the exercise of
employee options with respect to the majority acquisition of GENEART
Applied Biosystems Deutschland GmbH. Adjusted for this extraordinary
preliminary EBIT of GENEART AG totals EUR 635 thousand after nine months.
The prognosis for the fiscal year 2010 remains valid. GENEART expects net
in the range of EUR 19.5M, and an EBIT (in accordance with IFRS) of
This document may contain estimates, prognoses and opinions about company
and objectives, products or services, future results, opinions about
results or opinions leading up to these results. All these projections
future are subject to risk, uncertainty and unforeseeable change
control of the GENEART Group. Many factors may lead to actual results,
considerably deviate from the given projections for these results.
About GENEART AG:
In 2000 GENEART entered the Gene Synthesis market and has since
global market leader. Today, the company is one of the leading
the Synthetic Biology field. Experts at GENEART provide key technologies
development and production of new therapeutics and vaccines. Customers also
advantage of GENEART services to customize enzyme attributes, such
attributes of enzymes used as detergent additives, and to construct
which produce complex biopolymers or break down polymers, such as
petroleum components, etc. GENEART's service portfolio ranges from
optimization and production of synthetic genes according to DIN EN
9001:2008, to the generation of gene variants or complex gene libraries
production of cell lines, to the development and production of DNA and
based drug candidates. GENEART AG in Regensburg and its subsidiaries
Inc. in Toronto (Canada) and GENEART Inc. in San Francisco (USA) employ
180 people. The company is listed on the German Stock Exchange since May
Since April 2010, U.S.-based Life Technologies Corporation, one of the
biotechnology companies worldwide with 2009 revenues of USD 3.3B and
9,000 employees, is the majority shareholder of GENEART AG.
--- End of Message ---
Josef-Engert-Str.11 Regensburg Germany
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Open Market (Freiverkehr) in Frankfurter Wertpapierbörse;
GENEART AG: Preliminary Group Results (IFRS) for QIII/2010:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Geneart AG via Thomson Reuters ONE